JPRN-UMIN000017828已完成2 期
Phase II trial of the addition of bevacizumab to alectinib beyond progressive disease in ALK-positive advanced non-small-cell lung cancer. - Phase II study of alectinib and bevacizumab for ALK-positive NSCLC (NLCTG1501)
iigata Lung Cancer Treatment Group0 个研究点目标入组 11 人开始时间: 2015年6月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Have hemosputum more than 2.5ml 2)Evidence of bleeding diathesis 3)Evidence of tumor invading a perihilar blood vessel or cavitation in intra-thoracic lesion on imaging 4)Evidence of thombosis on imaging 5)Have had or require continuous administration of warfarin, heparin, or aspirin at the dose of more than 324mg per day. 6)Have uncontrolable hypertension 7)Have interstital pneumonia or idiopathic pulmonary fibrosis on CT 8)Have grade 2 or more non-hematological toxicity by alectinib 9)Have symptomatic brain metastases 10)Radiotherapy for primiary lesion 11)Have any severe disease complications 12)Have severe infection including hepatitis B which requires anti-virus agents. 13)Have a history of active double cancer 14)Have severe digestion and absorption disorder 15)Have severe mental disorder 16)Patients whose participation in the trial is judged to be in appropriate by the doctor
研究者
相似试验
已完成
2 期
Phase II Trial of Bevacizumab in Combination with XELOX in Colorectal Cancer Patients with Liver Metastases (H2, H3)colorectal liver metastasesJPRN-UMIN000002897iigata Colorectal cancer Chemotherapy Study Group (NCCSG)20
招募中
1 期
Phase I/II Trial of Bevacizumab in Combination With FOLFOXIRI As First-Line Therapy in Colorectal Cancer Patients With Liver Metastasescolorectal cancer patients with fore or more liver metastasesJPRN-UMIN000005413Yokohama City University School of Medicine23
招募中
不适用
Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.Breast CancerJPRN-UMIN000010466Kansai medical university23
进行中（未招募）
不适用
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
已完成
2 期
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapymetastatic colorectal cancerJPRN-UMIN000002407Sapporo City General Hospital20